Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).

    Comp Immunol Microbiol Infect Dis 2007 Sep 3;30(5-6):391-8. Epub 2007 Jul 3.
    Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan.
    Ebola viruses (EBOV) and Marburg virus belong to the family Filoviridae, order Mononegavirales. The genus Ebolavirus consists of four species: Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Ivory Coast ebolavirus (ICEBOV) and Reston ebolavirus (REBOV). Three species of ebolaviruses, ZEBOV, SEBOV, ICEBOV, and Marburg virus are known to be extremely pathogenic in primates and humans and cause severe hemorrhagic fever leading up to case fatality rate of some 90%, while REBOV is thought to be pathogenic in Asian monkeys but not in African monkeys and humans. Recent studies indicated several factors involved in different virulence between African EBOV and REBOV. This article reviews the history, epidemiology, and virulence of REBOV.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with
    Source Status ListingPossible

    Similar Publications

    Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β -/- interferon receptor-deficient mice.
    J Med Microbiol 2012 Jan 18;61(Pt 1):8-15. Epub 2011 Aug 18.
    Defence Science and Technology Laboratories (Dstl), Porton Down, Salisbury, Wiltshire, UK.
    Normal immunocompetent mice are not susceptible to non-adapted filoviruses. There are therefore two strategies available to establish a murine model of filovirus infection: adaptation of the virus to the host or the use of genetically modified mice that are susceptible to the virus. A number of knockout (KO) strains of mice with defects in either their adaptive or innate immunity are susceptible to non-adapted filoviruses. Read More
    Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    J Virol 2006 Mar;80(6):2738-46
    Division of Biodefense Vaccines, GenPhar, Inc., 871 Lowcountry Blvd., Mount Pleasant, South Carolina 29464, USA.
    Ebola virus (EBOV) causes a severe hemorrhagic fever for which there are currently no vaccines or effective treatments. While lethal human outbreaks have so far been restricted to sub-Saharan Africa, the potential exploitation of EBOV as a biological weapon cannot be ignored. Two species of EBOV, Sudan ebolavirus (SEBOV) and Zaire ebolavirus (ZEBOV), have been responsible for all of the deadly human outbreaks resulting from this virus. Read More
    Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin.
    Biochem Biophys Res Commun 2011 Apr 6;407(1):74-8. Epub 2011 Mar 6.
    Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo 113-0033, Japan.
    Ebola virus (EBOV) infection is initiated by the interaction of the viral surface envelope glycoprotein (GP) with the binding sites on target cells. Differences in the mortality among different species of the Ebola viruses, i.e. Read More
    Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
    J Virol 2009 Jul 22;83(14):7296-304. Epub 2009 Apr 22.
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
    The filoviruses Marburg virus and Ebola virus cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (VSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Here, we performed a proof-of-concept study in order to determine the potential of having one single-injection vaccine capable of protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV). Read More